Myriad Genetics (MYGN) Rating Reiterated by Barclays

Barclays reaffirmed their hold rating on shares of Myriad Genetics (NASDAQ:MYGN) in a report published on Monday morning. Barclays currently has a $30.00 target price on the stock.

Other analysts also recently issued reports about the company. Cowen reiterated a hold rating and set a $25.00 price target on shares of Myriad Genetics in a report on Sunday, September 17th. Leerink Swann reiterated a market perform rating and set a $31.00 price target on shares of Myriad Genetics in a report on Monday, October 2nd. Deutsche Bank increased their price target on Myriad Genetics from $28.00 to $30.00 and gave the stock a hold rating in a report on Wednesday, November 8th. Stephens set a $45.00 price target on Myriad Genetics and gave the stock a buy rating in a report on Wednesday, January 3rd. Finally, ValuEngine downgraded Myriad Genetics from a buy rating to a hold rating in a report on Thursday, November 2nd. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and three have issued a buy rating to the company. The company has a consensus rating of Hold and a consensus target price of $30.09.

Shares of Myriad Genetics (MYGN) traded up $0.72 during trading on Monday, reaching $35.53. The company’s stock had a trading volume of 492,700 shares, compared to its average volume of 491,313. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.06 and a current ratio of 2.34. Myriad Genetics has a 52-week low of $15.15 and a 52-week high of $37.30. The firm has a market cap of $2,460.00, a P/E ratio of 24.01, a P/E/G ratio of 2.21 and a beta of 0.24.

Myriad Genetics (NASDAQ:MYGN) last issued its quarterly earnings results on Tuesday, November 7th. The company reported $0.26 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.21 by $0.05. Myriad Genetics had a return on equity of 9.54% and a net margin of 13.28%. The firm had revenue of $190.20 million during the quarter, compared to the consensus estimate of $183.52 million. During the same period last year, the business posted $0.23 EPS. The business’s revenue was up 7.2% compared to the same quarter last year. analysts forecast that Myriad Genetics will post 1.05 earnings per share for the current fiscal year.

In other news, insider Alexander Ford sold 3,031 shares of the firm’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $31.64, for a total value of $95,900.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Heinrich Dreismann sold 6,000 shares of the firm’s stock in a transaction dated Monday, December 11th. The shares were sold at an average price of $33.50, for a total value of $201,000.00. Following the completion of the sale, the director now owns 33,743 shares of the company’s stock, valued at $1,130,390.50. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 16,531 shares of company stock valued at $545,826. 6.70% of the stock is currently owned by company insiders.

A number of hedge funds have recently added to or reduced their stakes in MYGN. SG Americas Securities LLC acquired a new position in Myriad Genetics during the 2nd quarter valued at about $101,000. Bank of New York Mellon Corp boosted its stake in Myriad Genetics by 1.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 935,217 shares of the company’s stock valued at $24,165,000 after purchasing an additional 16,912 shares during the last quarter. Legal & General Group Plc boosted its stake in Myriad Genetics by 8.2% during the 2nd quarter. Legal & General Group Plc now owns 131,723 shares of the company’s stock valued at $3,403,000 after purchasing an additional 10,023 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Myriad Genetics by 3,137.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 206,529 shares of the company’s stock valued at $5,337,000 after purchasing an additional 200,150 shares during the last quarter. Finally, Fiduciary Trust Co. acquired a new position in Myriad Genetics during the 2nd quarter valued at about $113,000.

ILLEGAL ACTIVITY WARNING: “Myriad Genetics (MYGN) Rating Reiterated by Barclays” was published by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.com-unik.info/2018/01/12/myriad-genetics-mygn-rating-reiterated-by-barclays.html.

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Analyst Recommendations for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit